Royalty Report: Drugs, cardiac, Disease – Collection: 328338

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Drugs
  • cardiac
  • Disease
  • Drug Discovery
  • Therapeutic
  • Delivery
  • Diagnostic
  • Biotechnology
  • Surgical
  • Medical
  • Device
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 328338

License Grant
Licensor grants the Licensee of Japan the right and license, with no right to sublicense except as provided under the Licensor Patents and the Know-How, solely to use the Licensed Compounds to conduct Development and to import, use, and sell Products solely for use in the Field within the Territory.

For Other Indications for Licensed Compounds, Licensor grants a right of first refusal to obtain licenses to use Licensed Compounds for other applications or indications outside the Field.

For Rights to Related Compounds. Licensor grants the right to include within the license rights granted under the License specific Related Compounds.

The Parties are to develop  and  commercialize LR-3280 and certain related oligonucleotide compounds in Japan and certain other countries in Asia for the prevention or treatment of restenosis in any blood vessel  following an angioplasty or similar procedure,  and Licensor will supply Licensee quantities of product containing such compounds for clinical use and commercial sale.

License Property
Licensor is engaged in research and  development of, among other things, oligonucleotides and oligonucleotide  analogs that may be useful for therapeutic treatment of disease conditions.   Licensor is presently developing  one such oligonucleotide compound, identified as LR-3280 targeted to c-myc mRNA, as a pharmaceutical product for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure.

The patents subject matter includes but is not limited to
–  Method of inhibition smooth muscle cell proliferation by treating with c-myc antisense;
–  Method of treating restenosis by administrating c-myr antisense;
–  Method of Inhibiting collagen synthesis by treating with c-myr antisense;
–  Method of treating vascular grafts to reduce stenosis by applying c-myr antisense to graft; and,
–  Pharmaceutical compositions for the above methods.

Licensed Compounds means the oligonucleotide compound identified by Licensor as LR-3280, and any other phosphorothioated oligonucleotidc compounds that now or hereafter are owned or Controlled by Licensor or its Affiliates and that specifically target the mRNA transcribed from the c-myc gene, or contain four deoxyguanosine nucleotides in a row and are developed by Licensor for use in the Field.

Clinical Trial Product means a product,  appropriate for use in clinical trials, containing a Licensed  Compound or placebo, as applicable, in the formulation as determined by Licensee.

Field of Use
Field means the prevention or treatment of restenosis in humans in any blood vessel by use of a Licensed Compound delivered to the affected blood vessel via a Delivery Means following any stenosis-reducing medical procedure that is Transient in nature and that is intended to reduce the obstruction of the blood flow in a stenosed vessel (including without limitation percutaneous transluminal angioplasty, percutaneous transluminal coronary angioplasty and angioplasty involving placement of an intravascular stent).

Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.

IPSCIO Record ID: 230823

License Grant
Licensor grants to an irrevocable, worldwide, sublicensable, exclusive license to the Technology to make, have made, use, import, export, distribute, sell, offer to sell and have sold the Drug in the Field and to make, have made, use, import, export, distribute, sell, offer to sell and have sold products incorporating or utilizing the Drug and/or the Technology in the Field, practice methods covered thereby, and otherwise to commercialize and exploit, the Drug and/or the Technology in the Field.
License Property
Licensor has developed technology relating to antisense compounds, including Resten NGâ„¢.

Resten-NG is a third-generation NeuGene® antisense compound, is designed to address the underlying genetic mechanism that leads to restenosis. The result is that this compound can selectively target multiple aspects of the restenosis response, specifically cellular proliferation, secretion of matrix proteins and inflammation, potentially without impeding vascular healing.  Restenosis is the renarrowing or reclogging of arteries following balloon angioplasty or placement of a stent.  Resten-NG is currently in Phase II clinical trials.

Compound means any drug as defined in the Federal Food, Drug and Cosmetic Act, as amended, not licensed hereunder and all derivatives and analogues of such drug, any biological product as defined in the Public Health Service Act, as amended, not licensed hereunder and all derivatives and analogues of such biological product and the antisense compounds not licensed hereunder.

The patents include morpholino-based polymers, sequence-specific polynucleotide-binding polymers, antisense oligonucleotides, and, method for blocking proliferation of a non-transformed cell in vivo or in vitro.

Field of Use
Field means the treatment of vascular disease only in conjunction with the use of a stent, balloon, catheter or any other medical device (other than a medical device providing for systemic application). The parties acknowledge that the Field docs not include the treatment of hypertension or congestive heart failure except as may occur through the treatment of restenosis or atherosclerosis.

IPSCIO Record ID: 223114

License Grant
In consideration of the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Canadian Licensee and Licensor agree to amend the agreement.  The Parties wish to allow Licensee additional time to submit royalty reports and royalty payments under the Original Agreement and to modify the method of measuring the value of access to the valid and enforceable Licensed Patent Rights with respect to certain Licensed Products.

The Original Agreement by and between Licensor and Licensee grants Licensee, among other things, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.

License Property
Llcensed Patent Rights shall mean U.S. Patents and Patent Applications.

5,616,608 – Method of treating atherosclerosis or restenosis using microtubule stabilizing agent

Field of Use
This Agreement pertains to the drug industry relating to the Fields of Use for treatment of coronary restenosis and/or atherosclerosis.

Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.

Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.

IPSCIO Record ID: 369310

License Grant
The University grants an exclusive worldwide license to make, have made, use, sell, have sold, offer for sale, import, and otherwise obtain or provide Licensed Products and a non-exclusive worldwide license to use Technical Information.
License Property
The patents and technical information relate to
Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof;
Device and method for treating restenosis;
Inhibition of Phosphatidylinositol 3-kinase with wortmannin analogs;
Device and Method for Treating Restenosis; and,
Wortmannin Analogs and Methods of Using Same.
Field of Use
Licensee is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer.

IPSCIO Record ID: 368507

License Grant
The Licensor, an individual, hereby grants to Licensee an exclusive license to practice under the Licensed Patents and use the licensed information, with the right to grant sublicenses, to make, have made, use, sell, have sold, offer to sell, import or export Licensed Products within the field in the licensed territory (the License).
License Property
The intellectual property portfolio for 2NTX-99 includes an issued U.S. patent and a pending Patent Cooperative Treaty submission relating to its composition of matter, multiple methods of manufacturing, and method of use in treating a variety of atheroclerotic-thrombotic pathological conditions.

U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled “Compound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.

Field of Use
2NTX-99 has potential utility in a range of atherosclerotic, thrombotic and microvascular diseases.

Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).

IPSCIO Record ID: 29398

License Grant
UNeMed hereby grants to Licensee and Licensee accepts, subject to the terms and conditions hereof, in the Territory and within the Field, an exclusive commercial license under Patent Rights, to make and have made, to use and have used, to sell and have sold the Licensed Products and to practice the Licensed Processes, for the life of the Patent Rights.
License Property
Title Sustained-Release Nanoparticle Compositions and Methods for Using the Same Serial Number 11/018,456.

The Corporation has secured, through the University, a field-of-use License to utilize a proprietary patented formulation of PLGA biodegradable nanoparticles in the lengthening of chromosomal telomeres.  PLGA biodegradable nanoparticles are an FDA approved gene therapy product that has been extensively investigated for sustained and targeted/localized delivery of different agents including plasmid DNA, proteins and peptides and low molecular weight compounds. Molecules much too large for traditional gene therapies can be encapsulated and delivered with PLGA. PLGA is non-toxic, does not illicit an immune response, and causes high transfection rates.

Field of Use
Field Development, manufacture or sale of any products which link the chromosomal telomeres to offset, reduce or reverse age-related diseases.

IPSCIO Record ID: 383599

License Grant
For the Product License, Licensor grants an exclusive license, with the limited right to sublicense, under the Licensed IP to research, develop, make, have made, use, sell, offer for sale, have sold, import and export Products in the Territory for therapeutic purposes.

For the Limited Right to Sublicense, the Product License is sublicensable only in connection with a sublicense of a Product to any Affiliate of Licensee or to any Third Party,

License Property
Licensor has intellectual property to advance mipomersen and related compounds targeting apoB.

Mipomersen means mipomersen sodium, including all pharmaceutically acceptable salts, solvates, hydrates, hemihydrates, metabolites, pro-drug forms, stereoisomers, enantiomers, racemates and all optically active forms thereof.

apoB means apolipoprotein B.

Product means all pharmaceutical compositions, formulations, dosage forms, delivery systems and presentations that contain Mipomersen or any Follow-On Compound as an active ingredient.

ASO Product any preparation in final form for sale by prescription, over-the-counter or any other method for any indication, including human or animal use, which contains one or more oligonucleotides or an analog thereof that  selectively modulates protein synthesis at the nucleic acid level through the binding of such oligonucleotide to a complementary sequence.

FH means familial hypercholesterolemia.

Licensed Product Patents means the Shortmer Patent, and any Patent Controlled by Isis during the Term, including any Licensor Program Patents and Joint Patents, claiming nucleic acids that hybridize to a nucleic acid molecule encoding apoB, the sequence of apoB. the specific composition of matter of a Product, or methods of using Product as a therapeutic, methods of using Product to modulate apoB, and methods of using the Product to inhibit expression of apoB- and also claiming or describing (x) nucleic acids that hybridize to a nucleic acid molecule encoding a gene target other than apoB or ( y) methods of using such nucleic acids as a therapeutic or to modulate a gene target other than apoB.

Field of Use
The field of use is to treat homozygous familial hypercholesterolemia.  Homozygous familial hypercholesterolemia is a disorder where it is hard for your body to remove LDL 'bad' cholesterol from your blood. The disease raises your chances of a heart attack at an early age, but drugs and other treatments can lower your risk.

Licensee will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk cardiovascular patients that utilizes novel antisense technology.  Mipomersen, formerly ISIS 301012, is a lipid-lowering drug targeting apolipoprotein B-100. Currently in phase 3 development, mipomersen has been shown in phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with current standard lipid-lowering drugs, enabling more patients to achieve lipid targets.

IPSCIO Record ID: 117698

License Grant
The parties co-promote INTEGRILIN in the United States and share any profits or losses. Outside of the United States, the Swiss Licensee markets INTEGRILIN exclusively.

With this amendment the Parties desire to modify their agreement to address such issue of sales allocation, and also with respect to the allocation of regulatory responsibilities in Canada, the manufacture and supply of Integrilin Product in Canada, and to set forth certain understandings regarding a Phase III clinical trial for Integrilin Product in the setting of acute myocardial infarction or AMI.

License Property
INTEGRILIN(R) (eptifibatide) Injection, is the only drug approved for use in both acute coronary syndromes and angioplasty procedures.
Field of Use
This agreement is for the pharmaceutical industry.
INTEGRILIN is indicated for the treatment of patients with an acute coronary syndrome and patients who undergo angioplasty procedures. The acute coronary syndrome indication includes patients with unstable angina and non-Q-wave myocardial infarction, whether they receive medical treatment or undergo angioplasty.

Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies.

Angioplasty, also known as balloon angioplasty and percutaneous transluminal angioplasty (PTA), is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins, typically to treat arterial atherosclerosis.

IPSCIO Record ID: 368502

License Grant
The Licensor grants to the Licensee of Russia a nonexclusive right and license, with the right to sublicense, under the Licensed Technology to conduct applicable clinical or related scientific trials for the registration of Licensed Compounds and/or Licensed Products in the Field and the Territory; and an exclusive right and license, with the right to sublicense, to use the Licensed Technology only for applications within the Field and in the Territory, including the rights to import, transfer, use, offer for sale and sell Licensed Compounds and/or Licensed Products in the Territory.
License Property
Licensor owns certain technology and patent rights regarding AHRO-001, an investigational drug candidate for the treatment of dyslipidemia and regression of atherosclerotic plaque.

Licensed Compounds shall mean AHRO-001 including all stereoisomers, polymorphs, prodrugs, analogs, active metabolites and salts of any of the foregoing further including any and all related backup compounds and analogs disclosed and claimed in the Licensor Patent Rights which are subsequently substituted for AHRO-001.

The patents include Dissolution of Arterial Plaque, and, Compositions and Methods for Treating Obesity.

Field of Use
AHRO-001 is in phase I clinical trials for the treatment of atherosclerosis.

Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries.  This process gradually restricts the blood flow to one's organs and tissues and can lead to severe health risks brought on by atherosclerosis, which is a specific form of arteriosclerosis caused by the buildup of fatty plaques, cholesterol, and some other substances in and on the artery walls.

The Field shall mean all human diagnostic and therapeutic applications of the Licensed Technology disclosed in the Licensor Patent Rights including without limitation the treatment of Dyslipidemia and the regression of atherosclerotic plaque.

IPSCIO Record ID: 223113

License Grant
In consideration of the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Canadian Licensee and Licensor, government organization, agree to amend the Original Agreement.  The Parties wish to adjust the earned royalty rates to reflect the additional intellectual property rights that were granted to the Licensee by another Party that is needed to practice the invention.  They also wish to further define the active components of certain Combined Products and to expedite the ultimate clinical use of Licensed Products which are at a later stage of development by severing certain legal obligations from other Licensed Products which are at earlier stages of development.

The Original Agreement by and between Licensor and Licensee grants Licensee, among other things, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.

Licensor grants Licensee an exclusive license in two different Licensed Fields of Use and a nonexclusive license in a third Licensed Field of Use.

License Property
Llcensed Patent Rights shall mean U.S. Patents and Patent Applications.

5,616,608 – Method of treating atherosclerosis or restenosis using microtubule stabilizing agent

Licensed Product(s) means tangible·materials which, in the course of manufacture, use, or sale would, in the absence of this Agreement, infringe one or more cl.aims of the Licensed Patent Rights that have not been held invalid or unenforceable by an unappealed or unapproachable Judgment of a court of compact jurisdiction.

Field of Use
Fields of Use is the treatment of coronary restenosis and/or atherosclerosis.

Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. And atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque. Initially, there are generally no symptoms.

IPSCIO Record ID: 372642

License Grant
Licensor, a nonprofit academic medical center, hereby grants to Licensee for the Term an exclusive, worldwide license to use the Licensed Technology in the Field of Use to (i) make, have made, develop, use, import, export, distribute, market, promote, offer for sale, and sell Products in the Field of Use, and (ii) practice in the Field of Use any method, process or procedure claimed within the Licensed Technology.
License Property
Licensed Patents
– U.S. Utility Application No.11/700,987, Filed 2/1/2007, “A METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSEL”, Henry Woo, MD, David Fiorella, MD, PhD. Publication Number US 20070208361 A1.

– U.S. Application No.60/764,206, Filed 2/1/2006, “A METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSEL”, Henry Woo, MD, David Fiorella, MD, PhD. Expired.

-U.S. Application No.60/793,588, Filed 4/20/2006, “A METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSEL”, Henry Woo, MD, David Fiorella, MD, PhD. Expired.

Field of Use
The license relates to its revascularization technology for the treatment of ischemic stroke.

Ischemic stroke occurs when a blood clot blocks or narrows an artery leading to the brain. A blood clot often forms in arteries damaged by the buildup of plaques (atherosclerosis). It can occur in the carotid artery of the neck as well as other arteries. This is the most common type of stroke.

IPSCIO Record ID: 344542

License Grant
The University grants an exclusive license, under the Licensed Patents, with the right to sublicense through multiple tiers, to make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, import, have imported, export or have exported Licensed Products, and to practice any Licensed Method, within the Field in the Licensed Territory.
License Property
The University has produced inventions pertaining to drug delivery using targeted nanoparticles OCR 1670 and 3070.

The Patents are for Methods of Treatment with Drug Loaded Polymeric Materials.

Field of Use
The Field shall mean the use of Licensed Products containing a polymer and a therapeutic agent for the treatment of cancer. The Field shall specifically exclude the use of Licensed Products for the treatment of brain cancer; for therapeutic or prophylactic cancer vaccines, including where such vaccines incorporate an adjuvant but not an antigen; and for therapeutic or prophylactic vaccines for infectious diseases or allergies.

IPSCIO Record ID: 223112

License Grant
Licensor, government public health organization, hereby grants and the Canadian Licensee accepts, subject to the terms and conditions of this Agreement an exclusive license for drug delivery system; and methods of treating fibroproliferative vascular diseases including restenosis and atherosclerosis utilizing local administration of mlcrotubule stabilizing agent, as encompassed by the subject patent(s) and/or patent application(s), including paclitaxel, watersoluble derivatives of paclitaxel, and deuterium oxide; and drug delivery systems and methods of treating fibroproliferative vascular diseases utilizing systemic, non-local administration of mlcrotubule stabilizing agents as encompassed by the subject patent(s) and/or patent application(s), excluding paclitaxel and water-soluble derivative, of paclitaxel; and a nonexclusive license for drug delivery systems and methods of treating restenosis and atherosclerosis utilizing systemic, non-local administration of paclitaxel and water-soluble derivatives of paclitaxel.
License Property
Llcensed Patent Rights shall mean U.S. Patents and Patent Applications.

5,616,608 – Method of treating atherosclerosis or restenosis using microtubule stabilizing agent

Licensed Product(s) means tangible·materials which, in the course of manufacture, use, or sale would, in the absence of this Agreement, infringe one or more cl.aims of the Licensed Patent Rights that have not been held invalid or unenforceable by an unappealed or unapproachable Judgment of a court of compact jurisdiction.

Field of Use
This agreement pertains to drug delivery systems and methods of treating fibroprolifertive vascular diseases.

Fibroproliferative vascular diseases include restenosis, using local and systemic administration of paclitaxel and other microtubule stabilizing agents.
Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. And atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque. Initially, there are generally no symptoms.

IPSCIO Record ID: 372578

License Grant
The original agreement between the Licensor of Sweden and Licensee is for selective inhibition ADP compound known as Cangrelor.

This amendment addresses performing the CHAMPION-PHOENIX Study, and financial considerations.

License Property
Cangrelor, a potent intravenous adenosine diphosphate-receptor antagonist, significantly reduced the rate of ischemic events, including stent thrombosis, during PCI without increasing severe bleeding when compared with clopidogrel, according to a late-breaking trial presented here.

CHAMPION-PHOENIX Study shall mean a repeat phase III prospective, randomized, double blind, standard clopidogrel care controlled, parallel group, superiority study in which the primary objective is to demonstrate that the efficacy of Cangrelor ( combined with 600mg of clopidogrel) is superior to that of usual care, in patients requiring percutaneous coronary intervention (PCI) as measured by a composite of all cause mortality, myocardial infarction (Ml), IDR and stent thrombosis which will be performed under US IND 56,812.

Ticagrelor Product shall mean Licensor s pharmaceutical product containing the pharmaceutical compound known as ticagrelor, a reversibly binding oral P2Y12 adenosine di phosphate (ADP) receptor antagonist.

Field of Use
The field of use is in patients undergoing percutaneous coronary intervention or PCI.  Cangrelor is used during percutaneous coronary intervention (PCI) for reducing the risk of heart attacks.  Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.